Action CVTX
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués CVTX

Actions

US1266671049

Cours en clôture Nasdaq
Autres places de cotation
- USD - Graphique intraday de CVTX

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
CV THERAPEUTICS : Gilead Sciences donne son accord pour l'acquisition de CV Therapeutics au prix de 20,00 USD par action
BU
CV THERAPEUTICS : CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer
PR
CV THERAPEUTICS : Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer
PR
CV THERAPEUTICS : CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal
PR
CV THERAPEUTICS : Statement on Unsolicited Proposal From Astellas
PR
CV THERAPEUTICS : FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
PR
CV THERAPEUTICS : to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
PR
CV THERAPEUTICS : Announces License Agreement for Ranexa(R) in Europe With Menarini Group
PR
CV THERAPEUTICS : Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
PR
CV THERAPEUTICS : Reports Option Grants Under Nasdaq Marketplace Rule 4350
PR
CV THERAPEUTICS : Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome
PR
CV THERAPEUTICS : Receives European Approval for the Brand Name Ranexa(R)
PR
CV THERAPEUTICS : Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
PR
CV THERAPEUTICS : CVT Announces That FDA Continues to Review Ranexa(R) Applications
PR
CV THERAPEUTICS : to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
PR
CV THERAPEUTICS : Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
PR
CV THERAPEUTICS : Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)
PR
CV THERAPEUTICS : Reports Option Grants Under Nasdaq Marketplace Rule 4350
PR
Cv Therapeutics : European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
PR
Cv Therapeutics : CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday, April 25, 2008
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action
  4. Actualités CVTX
  5. Communiqués